Atossa Genetics (ATOS) and Apollo Endosurgery (APEN) Head-To-Head Comparison

Atossa Genetics (NASDAQ:ATOS) and Apollo Endosurgery (NASDAQ:APEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares Atossa Genetics and Apollo Endosurgery’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atossa Genetics N/A N/A -$11.40 million ($5.50) -0.46
Apollo Endosurgery $60.85 million 1.30 -$45.79 million ($1.92) -1.88

Atossa Genetics has higher earnings, but lower revenue than Apollo Endosurgery. Apollo Endosurgery is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks.


This table compares Atossa Genetics and Apollo Endosurgery’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atossa Genetics N/A -136.07% -85.86%
Apollo Endosurgery -69.37% -97.89% -41.75%

Insider & Institutional Ownership

9.3% of Atossa Genetics shares are held by institutional investors. Comparatively, 39.3% of Apollo Endosurgery shares are held by institutional investors. 3.3% of Atossa Genetics shares are held by company insiders. Comparatively, 52.8% of Apollo Endosurgery shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Atossa Genetics and Apollo Endosurgery, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics 0 0 1 0 3.00
Apollo Endosurgery 0 2 0 0 2.00

Atossa Genetics presently has a consensus target price of $9.00, suggesting a potential upside of 252.94%. Apollo Endosurgery has a consensus target price of $3.50, suggesting a potential downside of 2.78%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Atossa Genetics is more favorable than Apollo Endosurgery.

Volatility & Risk

Atossa Genetics has a beta of 3.68, indicating that its share price is 268% more volatile than the S&P 500. Comparatively, Apollo Endosurgery has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.


Atossa Genetics beats Apollo Endosurgery on 7 of the 13 factors compared between the two stocks.

About Atossa Genetics

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

About Apollo Endosurgery

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.